KPI 1
Realized decarbonization
94.7
Measured change in Scope 1·2 and Scope 3 emissions.
V1-V2 · 2 variables
Back to companiesView all 12 variables and formulas
Pharmaceuticals
ScoredTakeda Pharmaceutical Company Limited (武田薬品工業)
CERs Index score of 65.8, with a 2030 reduction target in the public record.
Target Announced
65.8
CERs Index
FY2024 basis
Overall and four-KPI scores are available from the public evidence set.
Methodology
CERs v2 load
Score basis
FY2024 basis
Latest evidence
武田薬品工業 2025
CERs Index v1.5
Four KPI profile
These scores come from the same scoring run as the overall index. The frontend does not estimate missing values.
KPI 2
Target design & delivery
94.7
Target design completeness and on-track delivery.
W1-W2 · 2 variables
KPI 3
Capital allocation
19.1
Investment, revenue, carbon pricing, and governance alignment.
C1-C4 · 4 variables
KPI 4
Data credibility
54.6
Validation, assurance, completeness, and disclosure alignment.
A1-A4 · 4 variables
Roadmap
Carbon Neutral Roadmap
Current emissions, target point, and net zero milestone in one timeline.
Current 301,000
Target 2030 · 229,600
Net Zero —
Current emissions
301,000
tCO2e
Target year
2030
Public target point
Target emissions
229,600
tCO2e
Reduction vs current
65.0%
Net zero —
Transition pathway
Scope 1 Scope 2 Total
Sector comparison
Company score
Takeda Pharmaceutical Company Limited (武田薬品工業)
65.8
Sector average
Sector average
—
This company is near or below the current sector average. This view is designed to show relative transition quality within a comparable operating context.
Evidence overview
Read the disclosed target, emissions, assurance, and source document together with the KPI profile.
Target details
Baseline year
2016
Target type
Absolute Reduction
Coverage scope
Scope 1 100.000000%, Scope 2 100.000000%
Net zero target year
—
Interim target
Yes
SBTi status
Not disclosed